Status: Recruiting
High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10). This Phase 2b randomized, placebo-controlled, double-blinded trial will evaluate the efficacy and safety of RIF 35mg/kg compared 10mg/kg, added to standard first-line ATT, for the treatment of PCTB.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of Cape TownUpdated: Aug 21, 2025Locations: 2
Eligibility criteria
Aged >18 years [+6]
Glomerular filtration rate <30ml/min or renal failure requiring dialysis [+12]